The University of Illinois Hospital and its component institutions, the West Side Veteran's Administration (WSVA), and the Mount Sinai Medical Center serve a large minority population composed of African-American and Hispanic individuals. There is a long history of strong commitment from all three institutions to serve this population within the city of Chicago. The objectives of this grant renewal for the University of Illinois (UIC) Minority-Based CCOP (UIMBCCOP) are: 1. To continue to increase minority participation in clinical cancer research by implementing recruitment and retention goals in collaboration with participating primary care physicians, hospitals, and affiliated clinics; 2. To improve access to state-of-the-art treatment and cancer prevention and control research for minority individuals; 3. To increase the awareness, understanding, and involvement of health care providers, community leaders, and local organizations in UIMBCCOP activities; 4. To continue the extremely successful recruitment of African-American men to the SELECT trial and use this success to extend our participation in other cancer control activities. These objectives will be met by an established minority clinical research headquarters which utilizes the research bases of Cancer and Leukemia Group B (CALGB), Southwest Oncology Group (SWOG), Children's Oncology Group (COG), Gynecologic Oncology Group (GOG) through the M.D. Anderson Cancer Center, and the University of Michigan CCOP Research Base. The UIMBCCOP headquarters is located at University of Illinois and coordinates participation of patients from all three component institutions. Efforts will be increased to develop more effective affiliations with primary care sites (Mount Sinai Primary Care Network, Family Practice, General Internal Medicine, Women's Health, Chicago VA Health Care System primary care clinics). This will provide the patient base to allow better recruitment of minority patients to cancer control and prevention trials. The UIMBCCOP provides an identifiable center committed to excellence in cancer control for the underserved communities of Chicago. In this renewal we hope to more effectively bridge our efforts with the minority communities and improve cancer control and prevention efforts for those who are in most need.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA074811-09
Application #
6949090
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (J1))
Program Officer
Mccaskill-Stevens, Worta J
Project Start
1997-08-15
Project End
2007-05-31
Budget Start
2005-06-01
Budget End
2007-05-31
Support Year
9
Fiscal Year
2005
Total Cost
$873,874
Indirect Cost
Name
University of Illinois at Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
098987217
City
Chicago
State
IL
Country
United States
Zip Code
60612
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Cushman, Stephanie M; Jiang, Chen; Hatch, Ace J et al. (2015) Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Clin Cancer Res 21:1078-86
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Rizzieri, David A; Johnson, Jeffrey L; Byrd, John C et al. (2014) Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol 165:102-11
Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50

Showing the most recent 10 out of 68 publications